Cited by 104COVID-19 Clinical Research StudiesObesity, Physical Activity, DietCOVID-19 epidemiological studies

BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank

Open access
Sattar, Naveed, Ho, Frederick K., Gill, Jason MR., Ghouri, Nazim, Gray, Stuart R., Celis-Morales, Carlos A., Katikireddi, S. Vittal, Berry, Colin +3 more·2020·Diabetes & Metabolic Syndrome: Clinical Research & Reviews

Published version of a preprint

Abstract

Abstract We examined the link between BMI and risk of a positive test for SARS-CoV-2 and risk of COVID-19-related death among UK Biobank participants. Among 4855 participants tested for SARS-CoV-2 in hospital, 839 were positive and of these 189 died from COVID-19. Poisson models with penalised thin plate splines were run relating exposures of interest to test positivity and case-fatality, adjusting for confounding factors. BMI was associated strongly with positive test, and risk of death related to COVID-19. The gradient of risk in relation to BMI was steeper in those under 70, compared with those aged 70 years or older for COVID-19 related death (Pinteraction=0.03). BMI was more strongly related to test positivity (P interaction =0.010) and death (P interaction =0.002) in non-whites, compared with whites. These data add support for adiposity being more strongly linked to COVID-19-related deaths in younger people and non-white ethnicities. If future studies confirm causality, lifestyle interventions to improve adiposity status may be important to reduce the risk of COVID-19 in all, but perhaps particularly, non-white communities.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dsx.2020.06.060

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Empagliflozin (EMPA) exhibits potential therapeutic benefits for liver steatosis.

    “Empagliflozin (EMPA), a highly selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), exhibits potential therapeutic benefits for liver steatosis; however, the underlying mechanism remains incompletely elucidated.”

    From SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation (2024) · cites this paper as [20]

    The Conclusions (page unavailable) discuss BMI, adiposity, and COVID-19 risk, not treatment of liver steatosis. Searches for empagliflozin, SGLT2 inhibition, and steatosis found no passage addressing the claimed therapeutic benefit. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [3]Petrilli C.M. Jones S.A. Yang J. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City 2020 medRxiv 2020.04.08.20057794

Cited by

Sorted by citations

Authors
Sattar, N., Ho, F. K., Gill, J. M., Ghouri, N., Gray, S. R., Celis-Morales, C. A., Katikireddi, S. V., Berry, C., Pell, J. P., McMurray, J. J., & Welsh, P.
Affiliations
University of Glasgow (GB)
Corresponding author
Sattar, Naveed
Venue
Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Publisher
Elsevier BV
Published
2020-09
Volume
14
Issue
5
Pages
1149-1151
ISSN
1871-4021 (ISSN-L)
OpenAlex
W3039633474
Cited by
104
References
5
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 18 · 2022: 26 · 2021: 36 · 2020: 14
FWCI
3.08
Type
journal article
Language
en
Open access
Locations
  • Diabetes & Metabolic Syndrome Clinical Research & Reviews (publishedVersion, cc-by)
  • medRxiv (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
Funders
  • NS
  • British Heart Foundation (RE/18/6/34217)
  • Dasman Diabetes Institute
  • NRS Senior Clinical Fellowship (SCAF/15/02)
  • Medical Research Council (MC_UU_12017/13)
  • Scottish Government
  • Chief Scientist Office (SPHSU13)
  • Amgen
  • AstraZeneca
  • Lilly
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords
body mass index, adiposity, COVID-19 pandemic, COVID-19 mortality, case fatality, sex differences, age differences, ethnicity, South Asians, Afro-Caribbean, UK Biobank
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, Age Factors, Ethnicity, Female, United Kingdom, Humans, Male, Pneumonia, Viral, Prognosis, Risk Factors, Sex Factors, Body Mass Index, Survival Rate, Biological Specimen Banks, Coronavirus Infections, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review